Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 16, 2011

Mirus and Reinnervate to Commercialize 3-D Transfection Kits

  • Reinnervate and Mirus Bio inked an agreement to commercialize a range of products for transfecting cells cultured in 3-D. Mirus will produce and sell kits that combine its own TransIT®-3D tranfection reagent with Reinnervate’s alvetex® plates. The kits will be supplied with detailed protocols for achieving transfection of selected cell lines growing in 3-D.

    Alvetex is a polystyrene material developed by 3-D cell culture specialist Reinnervate, which the firm claims provides a scaffold that allows cells to grow and form 3-D structures that mimic normal growth and formation of tissues in the body. The platform has been tested and validated with a range of cell types, and is available in formats including a 12-well culture plate, 6-well and 12-well inserts, and a deep petri dish.

    U.K.-based transfection specialist Mirus Bio’s TransIT transfection reagents are designed to enable the efficient delivery of all types of nucleic acids and oligonucleotides to eukaryotic cells. The firm offers a range of transfection reagents and transfection kits, including cell line-specific products, reporter assays, and reagents/kits for the delivery of DNA, viral RNA, mRNA, siRNA, and oligonucleotides. The firm has in addition launched its TransIT-Pro Transfection kit for the production of proteins in CHO and 293 cells. 



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »